Summary
Global Markets Direct’s, ‘Merck KGaA - Product Pipeline Review - 2016’, provides an overview of the Merck KGaA’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Merck KGaA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Merck KGaA
- The report provides overview of Merck KGaA including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Merck KGaA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Merck KGaA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Merck KGaA’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Merck KGaA
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Merck KGaA’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Merck KGaA Snapshot 8
Merck KGaA Overview 8
Key Information 8
Key Facts 8
Merck KGaA - Research and Development Overview 9
Key Therapeutic Areas 9
Merck KGaA - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Partnered Products/Combination Treatment Modalities 18
Pipeline Products - Out-Licensed Products 20
Out-Licensed Products/Combination Treatment Modalities 21
Merck KGaA - Pipeline Products Glance 22
Merck KGaA - Late Stage Pipeline Products 22
Filing rejected/Withdrawn Products/Combination Treatment Modalities 22
Phase III Products/Combination Treatment Modalities 23
Merck KGaA - Clinical Stage Pipeline Products 24
Phase II Products/Combination Treatment Modalities 24
Phase I Products/Combination Treatment Modalities 25
Merck KGaA - Early Stage Pipeline Products 26
Preclinical Products/Combination Treatment Modalities 26
Discovery Products/Combination Treatment Modalities 27
Merck KGaA - Drug Profiles 28
cetuximab 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
avelumab 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
choriogonadotropin alfa 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
cladribine 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
atacicept 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
M-2736 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pimasertib hydrochloride 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
sprifermin 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
tecemotide 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
tepotinib 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BGB-283 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BGB-290 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DI-B4 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
L-Praziquantel 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
M-1095 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
M-2698 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
M-2951 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
M-3814 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
M-7824 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
M-9241 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MSC-2015103B 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pimasertib hydrochloride + voxtalisib 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
rimeporide 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ALX-0751 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AS-605240 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
cilengitide 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DDD-498 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
M-7583 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Monoclonal Antibody Conjugates for Oncology 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecule to Inhibit Aurora B Kinase for Cancer 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules to Inhibit CDK8 for Colorectal Carcinoma 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Vaccine 1 for Cancer 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Vaccine 2 for Cancer 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Inhibit SYK for Inflammation 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecule to Inhibit WNT Pathway for Oncology 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules for Autoimmune Disorder and Oncology 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules for Multiple Sclerosis 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Agonize TNFR for Cancer 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Merck KGaA - Pipeline Analysis 86
Merck KGaA - Pipeline Products by Target 86
Merck KGaA - Pipeline Products by Route of Administration 89
Merck KGaA - Pipeline Products by Molecule Type 90
Merck KGaA - Pipeline Products by Mechanism of Action 91
Merck KGaA - Recent Pipeline Updates 93
Merck KGaA - Dormant Projects 103
Merck KGaA - Discontinued Pipeline Products 105
Discontinued Pipeline Product Profiles 105
abituzumab 105
anastrozole 105
atacicept 106
cilengitide 106
cladribine 106
Drug to Antagonize Oxytocin Receptor for Pre-term Labor 106
EMD-1204831 106
emfilermin 106
EML-4156 106
M-1095 106
matuzumab 106
MSB-0010445 107
onercept 107
Osteopontin 107
pimasertib hydrochloride 107
plovamer acetate 107
sarizotan hydrochloride 107
tecemotide 107
tucotuzumab celmoleukin 108
Merck KGaA - Company Statement 109
Merck KGaA - Locations And Subsidiaries 112
Head Office 112
Other Locations & Subsidiaries 112
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123
List of Tables
Merck KGaA, Key Information 8
Merck KGaA, Key Facts 8
Merck KGaA - Pipeline by Indication, 2016 11
Merck KGaA - Pipeline by Stage of Development, 2016 14
Merck KGaA - Monotherapy Products in Pipeline, 2016 15
Merck KGaA - Combination Treatment Modalities in Pipeline, 2016 16
Merck KGaA - Partnered Products in Pipeline, 2016 17
Merck KGaA - Partnered Products/ Combination Treatment Modalities, 2016 18
Merck KGaA - Out-Licensed Products in Pipeline, 2016 20
Merck KGaA - Out-Licensed Products/ Combination Treatment Modalities, 2016 21
Merck KGaA - Filing rejected/Withdrawn, 2016 22
Merck KGaA - Phase III, 2016 23
Merck KGaA - Phase II, 2016 24
Merck KGaA - Phase I, 2016 25
Merck KGaA - Preclinical, 2016 26
Merck KGaA - Discovery, 2016 27
Merck KGaA - Pipeline by Target, 2016 86
Merck KGaA - Pipeline by Route of Administration, 2016 89
Merck KGaA - Pipeline by Molecule Type, 2016 90
Merck KGaA - Pipeline Products by Mechanism of Action, 2016 91
Merck KGaA - Recent Pipeline Updates, 2016 93
Merck KGaA - Dormant Developmental Projects,2016 103
Merck KGaA - Discontinued Pipeline Products, 2016 105
Merck KGaA, Subsidiaries 112
List of Figures
Merck KGaA - Pipeline by Top 10 Indication, 2016 10
Merck KGaA - Pipeline by Stage of Development, 2016 14
Merck KGaA - Monotherapy Products in Pipeline, 2016 15
Merck KGaA - Partnered Products in Pipeline, 2016 17
Merck KGaA - Out-Licensed Products in Pipeline, 2016 20
Merck KGaA - Pipeline by Top 10 Target, 2016 86
Merck KGaA - Pipeline by Route of Administration, 2016 89
Merck KGaA - Pipeline by Molecule Type, 2016 90
Merck KGaA - Pipeline Products by Top 10 Mechanism of Action, 2016 91
